Cancer vaccines are back, revitalized

Cancer vaccines are beginning to deliver positive clinical results, particularly in the adjuvant setting with lipo-nanoparticle mRNA formulations used to elicit neoantigen responses. In a recent report in Nature, Rojas et al. show this may even be possible in patients with pancreatic cancer. Cancer vaccines are beginning to deliver positive clinical results, particularly in the adjuvant setting with lipo-nanoparticle mRNA formulations used to elicit neoantigen responses. In a recent report in Nature, Rojas et al. show this may even be possible in patients with pancreatic cancer.